Chimeric Therapeutics (ASX:CHM) has moved to reassure investors of its strategic direction and clinical momentum, announcing a forthcoming refresh of its board and reaffirmed backing from major shareholders following its Annual General Meeting held on 25 November. …
Chimeric signals board refresh and shareholder support as lead trial advances
November 30, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
New treatment listed on PBS, offering twice-yearly dosing for Australians with relapsing MS
January 9, 2026 - - Latest News -
The value of looking back and the importance of seeing the 'smoke signals' on reform
January 8, 2026 - - Latest News -
Vaxxas appoints former global vaccines leader to head global commercialisation push
January 8, 2026 - - Australian Biotech -
Reform was justified because a committee prioritising clinical considerations was 'culturally' problematic
January 4, 2026 - - Latest News -
AdAlta and SHcell launch cancer collaboration to progress breakthrough CAR-T therapy
January 2, 2026 - - Australian Biotech -
Cabinet documents from the year that led to transformational changes
January 1, 2026 - - Latest News -
US pricing push gets real with Australia included in comparison list
December 22, 2025 - - Latest News